 |
|
|
Topics:
Plenary I Interview: Breast cancer 2011: What is the state of the art?
Current standards of care in the management of early and advanced breast cancer
Plenary II Interview: Fine-tuning the portrait of triple-negative breast cancer
The biology of triple-negative breast cancer and how it relates to therapeutic options
Plenary III Interview: Triple-negative breast cancer: On the pathway to better outcomes
Current and emerging therapeutic options for patients with triple-negative breast cancer
Plenary IV Interview: Exploring pathways to progress in breast cancer management
The rationale for therapeutic strategies for use of targeted therapy in breast cancer
 |
 |
|
Release Date
29 January 2011
|
Expiration Date
29 January 2012
|
|
|
Faculty
Fabrice André, MD, PhD
Institute Gustave Roussy
Villejuif, France
Lisa Carey, MD
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States
Joseph Gligorov, MD
Tenon University Hospital
Paris, France
Nadia Harbeck, MD, PhD
University of Cologne
Cologne, Germany
Gabriel Hortobagyi, MD, FACP
The University of Texas M. D. Anderson Cancer Center
Houston, Texas, United States
Cliff Hudis, MD
Memorial Sloan-Kettering Cancer Center
New York, New York, United States
Joyce O’Shaughnessy, MD
Baylor Sammons Cancer Center
US Oncology
Dallas, Texas, United States
Edith Perez, MD
Mayo Clinic—Jacksonville
Jacksonville, Florida, United States
Martine Piccart-Gebhart, MD, PhD
Institute Jules Bordet
Brussels, Belgium
Hope Rugo, MD
University of California San Francisco
San Francisco, California, United States
Sandra Swain, MD
Washington Hospital Center
Washington, DC, United States
Norman Wolmark, MD
Allegheny General Hospital
Pittsburgh, Pennsylvania, United States
|
Target Audience
This educational activity is designed for medical oncologists, radiation oncologists, surgical oncologists, pathologists, radiologists, and other healthcare providers involved and/or interested in the care of patients with breast cancer. |
Overview
The interviews highlight the most clinically relevant information presented at the 5th Annual International Breast Cancer Conference (IBCC5) in Paris, France, 29-31 January 2011. |
Educational Objectives
Upon completion of this educational activity, participants should be able to:
- Discuss updated efficacy and toxicity data for clinically available treatment options based on data summarized during the IBCC5 meeting
- Incorporate clinical data describing various therapeutic agents or strategies into clinical practice to improve remission and survival rates for patients with breast cancer
- Correlate toxicity and tolerability data for therapeutic agents used to treat breast cancer with their impact on survival as well as patient quality of life
- Describe the proposed mechanisms of action of new and emerging therapeutic combinations, including available products and agents in development, for the management of patients with breast cancer
- Incorporate clinical data describing various therapeutic agents or strategies into clinical practice to improve remission and survival rates for patients with breast cancer
- Explain the implications of genetic analysis and biomarkers on treatment selection and response as they currently relate to patients with breast cancer
|
Sponsorship Statement
This activity is sponsored by prIME Oncology. |
Accreditation Statement
prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians.
|
Credit Designation Statement
prIME Oncology designates this enduring Internet-based educational activity for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Each interview may provide the following credits:
- 2011511-1: Breast cancer 2011: What is the state of the art? (Piccart-Gebhart, Swain) - 0.50 CME credits
- 2011511-2: Fine-tuning the portrait of triple-negative breast cancer (Carey, Harbeck, & Wolmarki) - 0.50 CME credits
- 2011511-3: Triple-negative breast cancer: On the pathway to better outcomes (Hudis, Gligorov, & O’Shaughnessy) - 0.25 CME credits
- 2011511-4: Exploring pathways to progress in breast cancer management (Andre, Horotbagyi, Perez,& Rugo) - 0.50 CME credits
|
Method of Participation
There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online post test and activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology’s database. However, upon request, your CME credit certificate will be e-mailed to you.
Links to the post-tests are available on the activity selection page and video player pages.
|
Technical Requirements
To participate in this activity, your computer should have a processor the equivalent of Intel Pentium II 450 MHz or faster, with 128MB of RAM and a connection to the Internet.
Estimated time to complete activity: 105 minutes |
Support Statement
This educational activity is supported by sanofi-aventis Groupe Oncology.
|
Disclosure of Conflicts of Interest
In accordance with the ACCME Standards for Commercial Support, educational activities sponsored by prIME Oncology must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, and planning committee members participating in a prIME Oncology–sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
Dr André has disclosed that he and his spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
Dr Carey has disclosed that she and her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
Dr Gligorov has disclosed that he has received consulting fees from Roche and sanofi-aventis. None of these relationships will impact his ability to present an unbiased discussion.
Dr Harbeck has disclosed that she has received research support from Roche and sanofi-aventis. She has also received consultant fees or speakers’ bureau fees from Roche and sanofi-aventis. None of these relationships will impact her ability to present an unbiased discussion.
Dr Hortobagyi has disclosed that he has received consulting fees from Allergan, Inc.; Merck; Genentech; Novartis; sanofi-aventis; and Taivex Therapeutics Inc. He has also performed contracted research for Novartis. None of these relationships will impact his ability to present an unbiased discussion.
Dr Hudis has disclosed that he has received consulting fees from Genentech and Roche. He has also performed contracted research for Merck and Onyx Pharmaceuticals Inc. None of these relationships will impact his ability to present an unbiased discussion.
Dr O’Shaughnessy has disclosed that she has received consulting fees from Biogen Idec Inc; Bristol-Myers Squibb; Caris Diagnostics, Inc; Eisai Inc.; Genentech Inc.; GlaxoSmithKline; GTx, Inc.; F. Hoffman-La Roche Ltd; Johnson & Johnson; and sanofi-aventis. She has also received speakers’ bureau fees or other fees from Abraxis Bioscience LLC; Bristol-Myers Squibb; and sanofi-aventis U.S. None of these relationships will impact her ability to present an unbiased discussion.
Dr Perez has disclosed that she and her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
Dr Rugo has disclosed that she has received fees for non-CME services from Genomic Health Inc.; and GTx. She has also performed contracted research for Abbott Laboratories; Bristol-Myers Squibb; Genentech; GlaxoSmithKline; Merck; Novartis; and sanofi-aventis. None of these relationships will impact her ability to present an unbiased discussion.
Dr Swain has disclosed that she has received consulting fees from Genentech; Novartis; and Roche. She has also provided uncompensated consultation to sanofi-aventis. She has performed contracted research for Bristol-Myers Squibb; Genentech; Pfizer Inc; and Roche; and she has received travel support from sanofi-aventis. None of these relationships will impact her ability to present an unbiased discussion.
Dr Wolmark has disclosed that he and his spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
The employees of prIME Oncology have disclosed:
Amy Furedy, RN, OCN (clinical) – no real or apparent conflicts of interest
Julian Lee Lokey, MD (medical director) – no real or apparent conflicts of interest
Bojana Pajk, MD, MSc (medical director) – no real or apparent conflicts of interest
Heather Tomlinson, MA (editorial) – no real or apparent conflicts of interest
Susan H. Yarbrough, CCMEP (compliance) – no real or apparent conflicts of interest
|
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. prIME Oncology and the supporters of this activity do not recommend the use of any agent outside of the labeled indications.
|
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturers’ product information, and comparison with recommendations of other authorities.
|
|
|
| This educational activity is supported by
sanofi-aventis Groupe Oncology. |
 |
|
|
|
|
|
|
|
|
|
|
|
